Thursday, 27 February 2020, 1221 Avenue of the Americas, New York.

E-mail Tel: +44 203 780 4157


David Blackburn

NERA Economic Consulting, Washington, DC

Dr. Blackburn is a Director and Head of the Life Sciences Group. Dr. Blackburn's areas of expertise include intellectual property (IP), antitrust and competition policy, and econometric analysis. In his IP practice, he conducts research and prepares expert reports for patent, trademark, and copyright infringement disputes, and false and misleading advertising cases.

J. Mark Gidley

White & Case, Washington, DC

J. Mark Gidley chairs the White & Case Global Antitrust/Competition practice, which is the only such practice to have been named Competition Group of the Year for seven years by Law360. His practice focuses on mergers and acquisitions, cartel cases, class actions, and pharmaceutical antitrust cases, with an emphasis on trying antitrust cases.


13.00: Welcome coffee and registration

13.30: Chairs’ opening remarks

David Blackburn, NERA, Washington DC
Mark J. Gidley, White & Case, Washington DC

13.45: Keynote address

14.15: Killer acquisitions in the pharmaceutical sector

Is current legislation doing enough to protect consumers from the effects of killer acquisitions?  This session will attempt to answer this question with an in-depth look at pipeline acquisitions, and consider whether more could be done to prevent companies from buying-out product lines which could have developed into competition.

15.15: Coffee break

15.45: Pricing in pharmaceuticals

Increasingly, enforcement agencies are putting more pressure on pharmaceutical manufacturers to ensure their pricing is fair and transparent. As the number of states implementing pricing legislation is surging, it’s clear pricing remains a prominent issue in the pharmaceuticals industry. With focus shifting towards legislative remedies – is it enough? This session will consider whether the current methods in place to tackle pricing issues are adequate when addressing ills in the market.

16.45: An update on pharmaceutical anti-trust litigation  

This session will explore recent pharmaceutical litigation cases and how they are evolving. Our panellists will consider the effect of the Apotex Inc. vs Acorda Therapeutics case on so-called sham litigations, as well as taking a look at developments in blocking patent cases and the effect this may have on antitrust.

17.45: Chair’s closing remarks

David Blackburn, NERA, Washington DC
Mark J. Gidley, White & Case, Washington DC

18.00: Delegates are invited to attend a drinks reception kindly hosted by White & Case


1221 Avenue of the Americas, New York, 10020-1095 United States


  • "Very good speakers and presentations." Robert Maness, Charles River Associates

  • "The topics... included the most important issues of competition law facing the pharmaceutical as bio-tech industry today." Ankur Kapoor, Constantine Cannon 

Ticket Prices

Private Practitioner
Type Price Expires
Super Early $350 17 Jan 2020
Early $450 14 feb 2020
Standard $550 27 Feb 2020


In-house/government rate
Type Price
Standard $0